Genmab A/S announced today it has reached the fifth milestone in its daratumumab collaboration with Janssen Biotech, Inc. . The USD 10 million milestone payment was triggered by progress in the ongoing Phase III study which compares daratumumab in combination with bortezomib, melphalan and prednisone to bortezomib, melphalan and prednisone alone as front line treatment for patients who are not considered candidates for stem cell transplantation .
http://ift.tt/1OOh1pf
http://ift.tt/1OOh1pf
No comments:
Post a Comment